Pembrolizumab was associated with high response rates in surgically unresectable advanced desmoplastic melanoma.

Pembrolizumab showed an 89% objective response rate in unresectable desmoplastic melanoma, with a 37% complete response rate.

A research team co-led by UCLA investigators has found that pembrolizumab, an immunotherapy drug that helps the immune system ...

This article highlights recent research on breast cancer, lung cancer, melanoma, head and neck cancer, and hematologic malignancies.

Among a cohort of 27 patients with metastatic desmoplastic melanoma -- a deeply invasive, rare melanoma subtype with a high tumor mutation burden -- nine achieved a complete response to the single ...

Desmoplastic malignant melanoma is a distinct melanoma entity histologically subtyped into mixed and pure forms due to significantly reduced lymph node metastases in the pure form. Recent reports ...

After profiling desmoplastic melanoma tumors, the researchers discovered that the majority — 14 out of 17 patients – had high mutational activity. Further, when compared to other melanoma types, ...

Desmoplastic melanoma is a rare subtype of melanoma that is commonly found on sun-exposed areas, such as the head and neck, and usually seen in older patients. Treatment is difficult because these ...

TAMPA, Fla. (Jan. 10, 2018) - Desmoplastic melanoma is a rare subtype of melanoma that is commonly found on sun-exposed areas, such as the head and neck, and usually seen in older patients.

Tumors from desmoplastic melanoma, a rare cancer most commonly found on the head or neck, can often be shrunk significantly before surgery by an immunotherapy known as PD-1 blockade, a result that ...

Desmoplastic melanoma, an often deeply invasive disease occurring in older adults, showed a uniquely favorable response to neoadjuvant pembrolizumab in this small study.

Recently, patients with metastatic desmoplastic melanoma (DM) have been shown to respond more favorably to anti-PD1/PD-L1 therapy than other melanoma subtypes. Given this, we evaluated PD-L1/2 ...